Cargando…

987. Repeated Exposure to an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV): A Randomized, Observer Blind, Multicenter Study

BACKGROUND: The safety, immunogenicity, and efficacy associated with administration of of aQIV in children 6 months through 5 years of age was investigated.(1) Although enhanced immunogenicity in children was demonstrated for MF59-adjuvanted influenza vaccines after first administration, the impact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daly, Wendy, Ramsey, Keith, Forsten, Aino, Heijnen, Esther, Leav, Brett, Oberye, Janine, Zhang, Bin, Pacciarini, Filippo, Vesikari, Timo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253546/ http://dx.doi.org/10.1093/ofid/ofy210.824

Ejemplares similares

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study
por: Vesikari, Timo, et al.
Publicado: (2020)

Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine
por: Vesikari, Timo, et al.
Publicado: (2015)

Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany
por: Molnar, Daniel, et al.
Publicado: (2022)

Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine in Young Children at High Risk of Influenza-associated Complications: A Phase III, Randomized, Observer-blind, Multicenter Clinical Trial
por: Esposito, Susanna, et al.
Publicado: (2020)

A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2–10 years
por: Vesikari, Timo, et al.
Publicado: (2012)

Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers
por: Vesikari, Timo, et al.
Publicado: (2012)

Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study
por: Pepin, Stephanie, et al.
Publicado: (2016)

Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult population
por: Rumi, Filippo, et al.
Publicado: (2023)

2490. A Phase 1, Randomized, Observer Blind, Antigen and Adjuvant Dosage Finding Study to Evaluate the Safety and Immunogenicity of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects ≥65 Years of Age
por: Otten, Gillis, et al.
Publicado: (2018)

Correction to Lancet Psychiatry 2018; 5: 987–1012
Publicado: (2019)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study
por: van der Vliet, D., et al.
Publicado: (2021)

987. Retrospective Evaluation of Calcaneal Osteomyelitis Outcomes and Factors for Treatment
por: Fong, Rebecca, et al.
Publicado: (2022)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2023)

A Prospective Cohort Study on Pregnancy Outcomes of Persons Immunized with a Seasonal Quadrivalent Inactivated Influenza Vaccine during Pregnancy
por: Robinson, Christopher, et al.
Publicado: (2022)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
por: Poder, Airi, et al.
Publicado: (2023)

Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency
por: Kostinov, Mikhail P., et al.
Publicado: (2020)

Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in pregnant women: a randomized, observer-blind trial
por: Vesikari, Timo, et al.
Publicado: (2019)

987. Improving Patient Access to HIV Post-Exposure Prophylaxis with Pharmacist Involvement
por: Grossman, Katlyn H
Publicado: (2020)

Native Mass Spectrometry for the Study of PROTAC GNE‐987‐Containing Ternary Complexes
por: Sternicki, Louise M., et al.
Publicado: (2021)

The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom
por: Kohli, Michele A., et al.
Publicado: (2021)

An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population
por: Fochesato, Anna, et al.
Publicado: (2022)

The New Quadrivalent Adjuvanted Influenza Vaccine for the Italian Elderly: A Health Technology Assessment
por: Calabrò, Giovanna Elisa, et al.
Publicado: (2022)

Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D–Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media—A Double-Blind Randomized Clinical Trial in Finland
por: Vesikari, Timo, et al.
Publicado: (2016)

Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2022)

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
por: Kohli, Michele A., et al.
Publicado: (2022)

Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study
por: Piazza, Franco M., et al.
Publicado: (2021)

Corrigendum: Chinese species of Carinostigmus Tsuneki (Hymenoptera, Crabronidae), including three new species and a new record to China. ZooKeys 987: 115–134. https://doi.org/10.3897/zookeys.987.55317
por: Bashir, Nawaz Haider, et al.
Publicado: (2021)

Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study
por: Vesikari, Timo, et al.
Publicado: (2010)

BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma
por: Chen, Yan-Ling, et al.
Publicado: (2022)

Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)
por: Butler, Chris, et al.
Publicado: (2021)

Cost-Effectiveness of the Use of Adjuvanted Quadrivalent Seasonal Influenza Vaccine in Older Adults in Ireland
por: Nguyen, Van Hung, et al.
Publicado: (2023)

987. Clinical Epidemiology and Outcomes of Invasive Pulmonary Aspergillosis as a Complication of Respiratory Viral Infection in Hospitalized Patients
por: De Los Santos, Bertha A, et al.
Publicado: (2021)

Surgeon effects on cataract refractive outcomes are minimal compared with patient comorbidity and gender: an analysis of 490 987 cases
por: Hughes, Rachael, et al.
Publicado: (2023)

The Preparation of High-Purity Iron (99.987%) Employing a Process of Direct Reduction–Melting Separation–Slag Refining
por: Li, Bin, et al.
Publicado: (2020)

An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16
por: Ma, Liya, et al.
Publicado: (2022)

Rotavirus VP6 as an Adjuvant for Bivalent Norovirus Vaccine Produced in Nicotiana benthamiana
por: Malm, Maria, et al.
Publicado: (2019)

Rotavirus VP6 Adjuvant Effect on Norovirus GII.4 Virus-Like Particle Uptake and Presentation by Bone Marrow-Derived Dendritic Cells In Vitro and In Vivo
por: Tamminen, Kirsi, et al.
Publicado: (2020)

Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine
por: Blazevic, Vesna, et al.
Publicado: (2015)

987. Identification of Fungal Pathogens In Formalin-Fixed Paraffin-Embedded (FFPE) Tissues by Targeted Next-Generation Sequencing (NGS) Technology
por: Totten, Marissa C, et al.
Publicado: (2023)

Parenterally Administered Norovirus GII.4 Virus-Like Particle Vaccine Formulated with Aluminum Hydroxide or Monophosphoryl Lipid A Adjuvants Induces Systemic but Not Mucosal Immune Responses in Mice
por: Heinimäki, Suvi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k51rj28ovmfcbq12j5c02edg66